Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Ritobegron (KUC 7483 CL) in Healthy Males
NCT02259933Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2004
- Primary completion
- May 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in overactive bladder (OAB) comparing KUC 7483 CL with Placebo (2 arms). Primary endpoints: Number of subjects with abnormal findings in physical examination, Number of subjects with clinically significant changes in 12-lead ECG and 6 more. Started Feb 2004; status: completed.
02
Drugs
ritobegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02259933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259933.